Description

Nooglutyl Powder

Nooglutyl
CAS Number	112193-35-8
Molar Mass	268.225 g·mol−1
Chemical Formula	C11H12N2O6
IUPAC Name	N-[(5-Hydroxy-3-pyridinyl)carbonyl]-L-glutamic acid

Introduction

Nooglutyl Powder is a specialized research product meticulously crafted for scientific exploration, emphasizing its application in research and strictly avoiding any reference to human consumption. This powdered form of Nooglutyl serves as a valuable tool for researchers delving into its unique properties and potential benefits.

Key Characteristics

Nooglutyl is a substance recognized for its pharmacological characteristics, particularly its potential neuroprotective effects. As a member of the nootropic class, it has become a focus of research due to its possible impact on neurological health.

Research Applications

Nooglutyl Powder finds versatile applications in research domains, providing researchers with a tool to explore its potential benefits. Its applications extend to investigations into neuroprotection following stroke, chronic cerebral ischemia, and brain injury.

Research Benefits

Nooglutyl on Neuroprotection and Stroke

Studies suggest that Nooglutyl may have neuroprotective properties, particularly in the context of stroke. Research in this domain aims to understand its mechanisms of action and potential applications in protecting the brain from damage following a stroke.

Nooglutyl on Chronic Cerebral Ischemia

Preliminary research indicates that Nooglutyl may impact chronic cerebral ischemia, a condition characterized by reduced blood flow to the brain. Investigations into its effects on cerebral blood flow contribute to understanding its potential applications in addressing ischemic conditions.

Nooglutyl on Brain Injury

Research suggests that Nooglutyl may have potential applications in mitigating the effects of brain injury. Studies exploring its impact on neuronal recovery and regeneration contribute to understanding its potential therapeutic role in the context of brain injury.

Summary

Nooglutyl Powder, designed exclusively for research purposes, provides researchers with a unique avenue for investigating its potential benefits in neuroprotection following stroke, chronic cerebral ischemia, and brain injury. The distinctive characteristics of Nooglutyl make it a promising subject for further exploration in neurological and neuroscientific research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Garibova, Taissiya & Voronina, T. & Galaeva, I. & Krajneva, V. & Povorova, O.. (2005). P.5.065 Neuroprotective effect of nooglutylin rats with experimentally produced hemorrhagic and ischemic stroke. European Neuropsychopharmacology – EUR NEUROPSYCHOPHARMACOL. 15. 10.1016/S0924-977X(05)80467-5. [Read More].
2. Chekman1, I.S., Belenichev 2, I.F., Demchenko2, A.V., Bobrova3, V.I.,
   Kucherenko1, L.I., Gorchakova2, N.A., and Bukhtiyarova 2, N.V.1 O.O. Bogomolets National Medical University, Kyiv 2 Zaporizhia State Medical University, Zaporizhia 3 P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv. [Read More].
3. Novikov VE, Kovaleva LA. [The effect of nootropic agents on brain mitochondrial function in the dynamics of craniocerebral trauma from the age aspect] Eksperimental’naia i Klinicheskaia Farmakologiia. 1998 Mar-Apr;61(2):65-68. PMID: 9621180. [Read More].